2024.0911
[News] The HIRA Successfully Concludes 2024 International Symposium
The Health Insurance Review & Assessment Service Successfully Concludes 2024 International Symposium
- Discussion on Performance Evaluation of High-Cost Drugs Based on Real-World Data(RWD) -
The 2024 International Symposium hosted by the Health Insurance Review & Assessment Service (HIRA), led by President Kang Jung-Gu, was successfully held on August 28th (Wednesday) at the Ambassador Seoul Pullman, focusing on the Performance Evaluation of High-Cost Drugs Based on Real-Word Data(RWD).
This symposium was organized to address the increasing need for utilizing Real-World Data (RWD) in managing drug reimbursement systems, including the evaluation of high-cost medications. It aimed to share RWD utilization cases and experiences. The event saw the participation of over 300 individuals, including speakers from seven countries (such as the UK and Canada), as well as domestic and international healthcare experts and interested citizens.
In her keynote speech, Vandana Ayyar Gupta, a scientific advisor at the National Institute for Health and Care Excellence (NICE) in the UK, introduced the UK's experiences with Real-World Data (RWD) and the framework for Real-World Evidence (RWE) based on it. Following this, Soyoung Yi, Director General of the Pharmaceutical Performance Assessment Department at the Health Insurance Review & Assessment Service, highlighted the need for RWD and proposed future directions on the topic of sustainable access to high-cost medications based on RWD.
Following the keynote speech, the first session featured Professor Bor-Sheng Ko from the National Taiwan University Cancer Center, who presented on international trends and the current status in Taiwan regarding the evaluation of high-cost medications using RWD and RWE. Nicole Mittmann, Vice President at Canada’s Drug Agency, shared Canada’s challenges and experiences in Health Technology Assessment (HTA).
In the second session, Jatin K. Dave, Professor at University of Massachusetts Chan Medical School and Chief Medical Officer at MassHealth in Massachusetts, shared experiences with value-based contracts (VBC) using RWE related to high-cost medications. The session concluded with Claus Moldrup, Director of Data Analytics Center at the Danish Medicines Agency, presenting case studies on big data and RWE governance.
Additionally, a panel discussion was held with Jungsin Lee, Chair of the Pharmaceutical Benefits Assessment Committee of HIRA, and Yoonsoo Park, Chair of the Subcommittee for Economic Feasibility Evaluation of HIRA, serving as moderators. The discussion included insights from experts in academia, the pharmaceutical industry, and the Ministry of Health and Welfare.
Health Insurance Review & Assessment Service (HIRA) President Kang Jung-Gu said, "Based on the experiences shared by advanced healthcare countries during this symposium, we look forward to the development of our country’s RWD-based pharmaceutical policies."
[Attachment] 3 Event Photos
